The list now includes morphine sulfate, a drug used to treat severe pain, and epinephrine, a drug used to treat allergic reactions.
The new policies say the FDA doesn’t intend to take action against pharmacies for compounding products that are essentially copies of commercially available drugs or for supplying hospitals with drugs without receiving patient-specific prescriptions, as long as specific guidelines outlined in the policy are met.
More articles on pharmacy:
HHS unveils plan to distribute Gilead’s COVID-19 drug
Two-thirds of hospital pharmacies have reduced staff during COVID-19 pandemic, ASHP survey finds
New CMS rule could raise out-of-pocket drug costs
